Ohtawa M, Masuda N, Karasawa Y, Tojo H
Drug Metabolism and Pharmacokinetics Department, Sandoz Pharmaceuticals Ltd, Ibaraki, Japan.
Eur J Drug Metab Pharmacokinet. 1995 Jul-Sep;20(3):191-6. doi: 10.1007/BF03189669.
Fluvastatin (FV), a new cholesterol-lowering agent, has been studied for its effects on hepatic microsomal drug-metabolizing enzymes in male rats. FV was orally administered in dosages of 1, 5, and 30 mg/kg/day for 7 consecutive days. 3-Hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase activities were markedly decreased at all dose levels. The amount of microsomal protein and the contents of cytochromes P450 and b5 did not change. No induction of aniline hydroxylase, aminopyrine N-demethylase, testosterone hydroxylases (15 alpha-, 7 alpha-, 6 beta-, 16 alpha-, and 16 beta-), and UDP-glucuronosyltransferase were found. On the other hand, 7-ethoxycoumarin o-deethylase activity was slightly increased and lauric acid omega-1-hydroxylase activity tended to be decreased after treatment with FV.
氟伐他汀(FV)是一种新型降胆固醇药物,已对其在雄性大鼠体内对肝微粒体药物代谢酶的影响进行了研究。FV以1、5和30毫克/千克/天的剂量连续口服7天。在所有剂量水平下,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶活性均显著降低。微粒体蛋白量以及细胞色素P450和b5的含量未发生变化。未发现苯胺羟化酶、氨基比林N-脱甲基酶、睾酮羟化酶(15α-、7α-、6β-、16α-和16β-)和UDP-葡萄糖醛酸基转移酶有诱导作用。另一方面,用FV处理后,7-乙氧基香豆素O-脱乙基酶活性略有增加,月桂酸ω-1-羟化酶活性有降低趋势。